HematologyNews.net

Hematology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "Myelofibrosis"

Interim results from an open-label study have shown that long-term administration ( up to 48 weeks ) of its investigational therapy AMG 531 was generally well-tolerated and stimulated platelet product ...


An oral medication produces significant and lasting relief for patients with myelofibrosis, a debilitating and lethal bone marrow disorder, researchers at The University of Texas MD Anderson Cancer Ce ...


Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical tri ...


The results of phase III study evaluating a JAK 1/2 inhibitor for the treatment of polycythemia vera were presented at the 50th Annual Meeting of the American Society of Clinical Oncology ( ASCO ). ...


Beta-thalassemias are characterized by ineffective red blood cell ( RBC ) production, leading to anemia, iron overload, and organ failure. As current treatment options for beta-thalassemia are limited ...


Data from the largest clinical trial of myelofibrosis patients treated with Ruxolitinib ( Jakavi ) were presented at 56th Annual Meeting of the American Society of Hematology ( ASH ) in San Francisco ...


There are considerable advances in the understanding of the Philadelphia-chromosome (Ph)-negative myeloproliferative neoplasms ( MPN ) in the past 10 years including unraveling the mutation topography ...